As of 2025-05-18, the Relative Valuation of Anavex Life Sciences Corp (AVXL) is (7.92) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.32 USD, the upside of Anavex Life Sciences Corp based on Relative Valuation is -195.2%.
The range of the Relative Valuation is (4.86) - (10.05) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.6x - 18.5x | 14.3x |
| Forward P/E multiples | 8.9x - 20.6x | 14.8x |
| Fair Price | (4.86) - (10.05) | (7.92) |
| Upside | -158.4% - -220.8% | -195.2% |
| Date | P/E |
| 2025-05-12 | -15.70 |
| 2025-05-09 | -15.15 |
| 2025-05-08 | -15.72 |
| 2025-05-07 | -15.57 |
| 2025-05-06 | -15.11 |
| 2025-05-05 | -16.36 |
| 2025-05-02 | -17.19 |
| 2025-05-01 | -17.10 |
| 2025-04-30 | -17.44 |
| 2025-04-29 | -17.68 |
| 2025-04-28 | -17.59 |
| 2025-04-25 | -17.30 |
| 2025-04-24 | -17.35 |
| 2025-04-23 | -17.10 |
| 2025-04-22 | -16.91 |
| 2025-04-21 | -16.09 |
| 2025-04-17 | -16.43 |
| 2025-04-16 | -16.23 |
| 2025-04-15 | -16.75 |
| 2025-04-14 | -16.20 |
| 2025-04-11 | -16.27 |
| 2025-04-10 | -15.68 |
| 2025-04-09 | -16.01 |
| 2025-04-08 | -13.96 |
| 2025-04-07 | -15.30 |
| 2025-04-04 | -15.04 |
| 2025-04-03 | -15.24 |
| 2025-04-02 | -15.72 |
| 2025-04-01 | -14.73 |
| 2025-03-31 | -15.76 |
| 2025-03-28 | -16.01 |
| 2025-03-27 | -17.52 |
| 2025-03-26 | -17.19 |
| 2025-03-25 | -17.55 |
| 2025-03-24 | -17.65 |
| 2025-03-21 | -17.89 |
| 2025-03-20 | -18.23 |
| 2025-03-19 | -18.07 |
| 2025-03-18 | -17.10 |
| 2025-03-17 | -16.89 |
| 2025-03-14 | -17.32 |
| 2025-03-13 | -16.53 |
| 2025-03-12 | -16.34 |
| 2025-03-11 | -16.49 |
| 2025-03-10 | -16.51 |
| 2025-03-07 | -15.92 |
| 2025-03-06 | -15.77 |
| 2025-03-05 | -16.03 |
| 2025-03-04 | -15.44 |
| 2025-03-03 | -15.19 |